Association between MRI parameters and the MS severity scale: a 12 year follow-up study

**Arjan Minneboo, Bernard M.J. Uitdehaag,
Sjef P.J.H. Jongen, Hugo Vrenken, Dirk L. Knol,
Marianne A.A. van Walderveen, Chris H. Polman,
Jonas A. Castelijns, and Frederik Barkhof**

Chapter 3.4

Abstract

Objective: Several MRI parameters are known to be associated with short-term outcome in multiple sclerosis (MS) patients. The goal of this study was to identify brain MRI parameters that are associated with overall disease severity.

Methods: In 46 MS patients, short interval MRI data were obtained at baseline and at first follow-up (FU) after 3.3 years. Overall disease severity was expressed using the MS Severity Score (MSSS) based on assessments at last FU (on average after 12.2 years). MRI parameters included both lesion loads and atrophy measures. Average and change parameters were calculated for MRI parameters and subsequently used as independent variables in regression models. MSSS was the dependent variable.

Results: FU was obtained in 43/46 patients (94%) and median expanded disability status scale (EDSS) score increased significantly from 2.5 to 4.0. At last FU median MSSS was 4.3 (range 2.2 to 6.9). In univariate analyses, both change and crossectional T1-hypointense lesion lesion load (BHLL) and ventricular atrophy measures were associated with MSSS. A multiple regression model included the change parameter of BHLL. This model explained 20% of variance in MSSS, which increased to 34% when type of disease (relapsing remitting or secondary progressive), age and sex were entered additionally.

Conclusion: MRI measures of axonal loss are associated with higher overall disease severity in MS patients.

Introduction

In patients with multiple sclerosis (MS), prediction of long-term outcome in terms of clinical disability is important for both patients and clinicians. Natural history studies have identified clinical parameters that predict disability at long-term follow-up (FU).[1-8] Although these clinical parameters do have modest prognostic value for the development of clinical disability later in the disease, the highly variable disease course and outcome as measured by the expanded disability status scale (EDSS)[9] still remain largely unpredictable. Compared to data known from average disease progression in large groups of patients, models using clinical parameters refine the prediction of the time to reach EDSS 6 for the individual patient by only 30-40%.[6,10] Substantial variation remains unexplained by those models, stressing the need for additional (paraclinical) parameters associated with progression of disability. Magnetic resonance imaging (MRI) may be valuable for this purpose: it is widely used as a diagnostic tool for MS and plays an important role in the most recent diagnostic criteria.[11]

In most patients, typical MS lesions are seen on T2-weighted images and MRI helps to predict conversion to clinically definite MS (CDMS).[12] Studies that follow patients with a clinically isolated syndrome (CIS) from onset describe significant associations between lesion loads and disability at FU.[7;8,13-15] In the more advanced disease stage of CDMS, both cross-sectional and longitudinal studies show moderate associations between lesion loads on T2 or T1-weighted images and EDSS.[16-21,22-24,25-28] Compared to lesion loads, brain atrophy seems to be associated more strongly with (future) disability.[25,29-32] There is only limited data on the clinico-radiological association in the long-term, since only moderate duration of FU is available for most studies–this relationship is therefore largely unknown.[13,33] A long-term FU study on patients that presented with CIS found that associations between change in EDSS and change in T2 lesion load weaken over time.[13] Concern rises when translating these results to CDMS patients: are the already weak associations between MRI parameters and disability still valid at long-term FU?

The current study presents the 12- year clinical FU of a cohort from which two previous clinical and MRI observations have been reported previously.[27] Our aim was to develop a multi-parametric model with MRI parameters obtained during

the initial short FU period that are most strongly associated with overall disease severity as expressed by the MS Severity Score (MSSS) based on assessments at long-term FU.

Methods

Patients

The initial cohort[27] included 46 patients (28 women) with CDMS according to the Poser[34] criteria. Baseline observations were performed between 1989 and 1991. After a median period of 40 months, a second observation (first FU) was performed according to the same protocol. Clinical data including age at onset, disease duration at entry, disability (EDSS) at entry and at first FU (at the time of the second MRI), type of disease course: relapsing-remitting (RR) or SP[35] were available. Data on the use of disease modifying therapy (DMT) beyond the first FU visit were not systematically available–at the time of the first FU visit DMT were not available in the Netherlands. For long-term clinical observation (last FU), patients were contacted and hospital charts were reviewed for disability on the basis of EDSS. For 10 patients no recent hospital charts were available and EDSS was obtained by phone using a standard questionnaire.[36] To classify overall disease severity, we used the MSSS, in which EDSS-levels are adjusted for disease duration.[10;37] The institutional medical ethics committee approved the study and informed consent was obtained from every patient.

MRI

All patients had two scans: at baseline and at first FU. Scans were performed on a 0.6T machine (Technicare, Solon, Ohio, USA) using an identical protocol. Accurate repositioning was performed using internal landmarks. Axial T2 and T1-weighted spin-echo images (2755/60,120/2 and 450/28/4 [repetition time/echo time/excitations]) were obtained. Each series consisted of 19 slices with a slice thickness of 5 mm (1.25 mm gap), covering the whole brain. The T1-weighted spin-echo sequence at baseline was performed before and 5 to 10 minutes after the administration of 0.1 mmol/kg gadolinium-DTPA. At first FU no gadolinium was administered.

Gadolinium-enhancing lesion loads (GdLL, only baseline), hypointense T1 lesion loads (BHLL) and hyperintense T2 lesion loads (T2LL) were quantified by a single reader using an in-house developed, semi-automated thresholding technique. Baseline and first FU scans were evaluated during the same session. Lesion loads have been reported previously.[27] Additionally, we determined parenchymal and ventricular volumes on T1-weighted images. Intracranial volumes were determined on corresponding T2-weighted images. To control for differences in skull size, brain parenchymal fraction (BPF) and ventricular fraction (VF) were calculated by dividing parenchymal (BPF) and ventricular (VF) volumes by the intracranial volume.[38]

Statistical analysis, descriptive

Because most data were not normally distributed, medians and interquartile range (IQR) were used to describe the data. The skewed distribution also necessitated the use of non-parametrical statistical tests: Mann Whitney *U* test was used to evaluate differences in MRI parameters between subgroups when lowest and highest quartiles of MSSS at last FU are compared. Longitudinal MRI data were normalized for duration of FU between first and second MRI. To describe correlations between (changes in) MRI and clinical parameters, Spearman rank correlation coefficients were used.

Statistical analysis, multiple regression model

To find the MRI parameter(s) that are most strongly associated with disease severity at last FU, a model was composed using a forward selection approach. MSSS as determined at last FU was the dependent variable. Because of the relatively small group size, summary parameters were used to optimize model building. This approach decreases the number of independent parameters and enables the use of information at baseline, first FU and change parameters without loss of statistical power. The effects of high correlations between baseline and first FU parameters are also avoided this way. Average values were calculated for: T2LL, BHLL, BPF and VF (baseline value + first FU value / disease duration at baseline (years) + disease duration at first FU [years]). Furthermore, a change parameter was calculated for T2LL, BHLL, BPF and VF (first FU value–baseline value / interval (years) between baseline and first FU). Performance of the model is reported by

percentage of explained variance. All statistical procedures were performed using SPSS 12.0 for Windows.

Results

Clinical parameters

During long term FU, two patients died due to causes not related to MS and were excluded from the analysis. One patient was lost to FU and had to be excluded. Characteristics at baseline and first FU were not different between excluded and reported patients. Data on the remaining 43 patients (94% adherence rate) are presented here. At baseline, median age was 38 years (Table 3.10).

Table 3.10. Clinical characteristics

Measurement	Group (n=43)
Duration interval baseline–follow-up 1 (y)	3.3 (3.2 ; 3.6)
Duration interval follow-up 1–follow-up 2 (y)	8.6 (6.9 ; 10.3)
Duration interval baseline - follow-up 2 (y)	12.2 (10.4 ; 13.8)
Type MS at baseline (RR;SP)	27 ; 16
Age at baseline (y)	38 (33 ; 44)
Disease duration at baseline (y)	5.0 (2.4 ; 7.3)
Sex (female; male)	27 ; 16
EDSS at baseline	2.5 (2.0 ; 3.5)
EDSS at follow-up 1	2.5 (1.5 ; 5.0)
EDSS at follow-up 2	4.0 (3.5 ; 6.5)
MSSS (based on data from follow-up 2)	4.3 (2.2 ; 6.9)

RR = relapsing remitting; SP = secondary progressive; MSSS = MS Severity Score.

Twenty-seven patients had RRMS, the other 16 SPMS at interception. Median EDSS score at baseline and at the first FU was 2.5, and increased significantly to 4.3 (IQR 2.3–6.9) after an average of 12.2 years of FU, with death due to MS (EDSS 10) occurring in 2 patients. Patients with SPMS had significant higher MSSS compared to RRMS patients: 7.0 (IQR 3.3; 9.8) compared to 3.4 (1.8 ; 5.2), P=0.008.

MRI parameters

All patients had hyperintense lesions consistent with white matter MS lesions on the T2-weighted images. T2LL at baseline was highly variable (IQR 4.5; 32.4 ml) (Table 3.11).

Table 3.11. MRI characteristics

Measurement	Group (n=43)
T2LL baseline (ml)	14.1 (4.5 ; 32.4)
BHLL baseline (ml)	3.4 (0.8 ; 11.2)
Enhancement (yes/no)	18/25
BPF baseline	0.830 (0.802 ; 0.865)
VF baseline	0.0226 (0.0159 ; 0.0327)
T2LL follow-up 1 (ml)	22.2 (7.6 ; 46.7)
BHLL follow-up 1 (ml)	6.4 (1.3 ; 15.6)
BPF follow-up 1	0.820 (0.789 ; 0.862)
VF follow-up 1	0.0224 (0.0153 ; 0.0331)
Change in T2LL/y (ml/y)	1.4 (0.6 ; 2.8)
Change in BHLL/y (ml/y)	0.5 (0.1 ; 1.3)
Change in BPF/y (* 100)	-0.343 (-0.923 ; 0.000)
Change in VF/y (*100)	-0.0028 (-0.1461 ; 0.0073)

T2LL = hyperintense T2 lesion load; BHLL = hypointense T1 lesion load; BPF = brain parenchymal fraction; VF = ventricular fraction.

At baseline, a strong correlation between BHLL and T2LL was found (r=0.83, P<.001). At first FU, median T2LL increased to 22.2 ml. In all but two patients an accumulation of T2LL was observed, at a median rate of 1.4 ml/year (Table 3.11). BHLL had increased to 6.4 ml, at a median rate of 0.5 ml/year. The change in BHLL was not correlated with BHLL at baseline. However, changes in T2LL were moderately associated with T2LL at baseline (r=0.53, P<.001). BHLL was associated with VF at both baseline (r=0.63, P<.001) and first FU (r=0.74, P<.001). Median BPF had decreased at first FU from 0.830 to 0.820. VF increased most in patients with the highest quartile MSSS (from 0.0267 to 0.0357); in this group the baseline and FU VF was also statistically significantly higher compared to patients with the lowest quartile MSSS: 0.0185 compared to 0.0267 (P=0.034) and at first FU 0.0162 compared to 0.0357 (P=0.012). Both baseline and first FU lesion loads

(T2LL and BHLL) were not statistically significantly different between the group with highest quartile MSSS and the lowest MSSS quartile group. Accumulation of BHLL was higher in the group with highest quartile MSSS compared to the lowest MSSS quartile group (median 1.2 ml/year compared to 0.2 ml/year, *P*=0.043). No statistically significant differences in accumulation of T2LL were found between the two groups.

Table 3.12. Linear regression: univariate analysis

Parameter	Beta	P value	Adjusted R^2
T2LL baseline (ml)	0.26	0.092	0.05
BHLL baseline (ml)	0.40	0.008	0.14
BPF baseline	-0.18	0.275	0.03
VF baseline	0.31	0.063	0.07
T2LL follow-up 1 (ml)	0.29	0.064	0.06
BHLL follow-up 1 (ml)	0.44	0.004	0.17
BPF follow-up 1	-0.21	0.211	0.02
VF follow-up 1	0.42	0.010	0.15
Change in T2LL/y (ml/y)	0.26	0.087	0.05
Change in BHLL/y (ml/y)	0.44	0.003	0.18
Change in BPF/y	0.02	0.920	0.00
Change in VF/y	0.35	0.033	0.10

T2LL = hyperintense T2 lesion load; BHLL = hypointense T1 lesion load; BPF = brain parenchymal fraction; VF = ventricular fraction. Adjusted R^2 = explained fraction of variance in MSSS at last follow-up.

Linear regression models

In the univariate analysis, both change and crossectional lesion (BHLL) and atrophy (VF) measures were associated with MSSS (Table 3.12).

To create a model with the MRI parameters that are most strongly associated with disease severity represented by MSSS score, the following summary parameters were used in a forward selection procedure; GdLL (baseline only), average and change of T2LL, BHLL, BPF and VF. The final MRI model contained the change parameter of BHLL only. This model was uncorrected for clinical parameters and explained 20% of the variance in MSSS. After inclusion of type of disease course (RR or SP), age and sex in the model, the change parameter of BHLL survived in the forward analysis. The percentage of explained variance in MSSS increased to 34%.

Discussion

Studies concerning associations between changes in lesion loads and concomitant disability changes or changes in disability at long-term FU are sparse in MS. Most of these studies included patients directly from onset and have reported moderate associations between (change in) MRI and disability.[8,13,15] A study on these associations where patients were followed from onset of the disease showed associations to decrease in strength over time.[13] A possible explanation could be the noise introduced due to the large number of patients lost to FU. On the other hand, a recent study reported the increasing predictive value of conventional MRI measures for clinical outcome during (13 years) FU.[33]

The current study included MS patients with varying disease duration that were followed-up for a median of 12 years, enabling classification of disease severity (MSSS) in a reliable way. Despite being small, our study had the benefit of having a low number of patients that were lost to FU (6%). Main outcome is that in a group of CDMS patients with varying disease duration, MRI parameters reflecting axonal loss (BHLL and ventricular widening) are associated with the higher disease severity at long-term FU. Change in BHLL was included in the final multivariate logistic regression model. Recently, stratification of patients was proposed using measures similar to those included in our final model: using black hole fraction as measure for focal brain tissue destruction. That model also included atrophy as measure for diffuse brain tissue destruction, a measure that was associated with MSSS in our study as well.[39] Their longitudinal observations showed these stratified groups to be distinct at baseline and FU and thus not to represent different stages of the disease.

Brain atrophy is present from the earliest stages of MS. Besides cross-sectional associations between atrophy and clinical status, as measured by the EDSS or scales of cognitive function, there are numerous short-term FU studies that show these associations may also exist longitudinally.[26,30-32,40-44] Previous studies extended these findings with FU durations of 6 and 8 years.[25,29] and recently a 13 year FU study was published.[33] No atrophy measures (independently) made it into our final model but the univariate analysis shows these measures still remain important during long-term FU and confirms the unfavourable impact of atrophy on disease progression.

BHLL is thought to represent focal brain tissue destruction and axonal loss more specifically than T2LL.[22-24] Therefore, it is not surprising that associations with clinical status improve in most studies when BHLL is used rather than T2LL. This applies to cross-sectional and short-term longitudinal studies.[23,25-28,45] Our observations suggest that the impact of BHLL on disease progression is also valid during long-term FU. Several studies reported on the associations between BHLL and (central) brain atrophy measures like VF in the various stages of the disease.[46-49] It is thought that destructive T1-hypointense lesions in the periventricular regions lead to local axonal loss and decreasing volume of braintissue with subsequently enlarging ventricles. In some studies BHLL and disease severity were not associated.[15] This may depend on the disease duration, overall disease severity and prevalence of T1-hypointense lesions in the studied population: the present study included patients with well established MS with relatively high BHLL.

A limitation of (longitudinal) studies on differences in the progression of disability between groups of patients is the lack of reliable classifying methods. The EDSS is the most widely used method to classify MS related disability. Several limitations, including the lack of correction for disease duration and its non-linearity have been reported.[50;51] Regarding these limitations, we did not use the annualized change in EDSS to determine the progression of disability during FU. The retrospective character of the study with EDSS measured at only three time-points also precluded the use of the exact time to reach EDSS 4 (or other values of the EDSS). Instead, we used the MSSS to classify disease severity: the MSSS provides a tool to compare the severity of the disease course between patients and is based on EDSS score adjusted for disease duration.

Weaknesses of the study can be divided in both MRI (performed at only 0.6T [at that time state-of-the-art], impossibility to use more sophisticated brain volume change methods rather than the more 'noisy' BPF and VF measures) and clinical limitations (partial use of EDSS by phone, small group size and limited information on the use of DMT and relapse rate). Although use of DMT could not be included in the analysis, this probably has not affected our results: DMT is known to effect the progression on MRI but our MRI measurements were obtained before DMT became available. Although some patients started using DMT between the first and last FU, this probably did not effect our results either since, until now, no major effects of DMT on long-term disability have been reported but several studies indicate that some benefit may be expected.[52;53]

In conclusion the findings of our study support the idea that MRI measures of axonal loss are associated with clinical status at long-term FU.

Acknowledgements

References

1. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. *Brain* 1980;103:281-300.

2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. *Brain* 2003;126:770-82.

3. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. *Brain* 2006;129:595-605.

4. Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, Nyland HI. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. *Mult.Scler.* 2001;7:59-65.

5. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. *Brain* 1993;116 (Pt 1):117-34.

6. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. *Brain* 1991;114 (Pt 2):1045-56.

7. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. *Brain* 1993;116 (Pt 1):135-46.

8. O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. *Brain* 1998;121 (Pt 3):495-503.

9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33:1444-52.

10. Weinshenker BG. The natural history of multiple sclerosis. *Neurol.Clin.* 1995;13:119-46.

11. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den NS, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann.Neurol.* 2001;50:121-7.

12. Korteweg T, Tintore M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, Fernando K, Filippi M, Agosta F, Rocca M, Fazekas F, Enzinger C, Matthews P, Parry A, Polman C, Montalban X, Barkhof F. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. *Lancet Neurol.* 2006;5:221-7.

13. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. *N.Engl.J.Med.* 2002;346:158-64.

14. Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. *Neurology* 1994;44:635-41.

15. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. *Arch.Neurol.* 2004;61:217-21.

16. Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. *Neurology* 1994;44:635-41.

17. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. *Brain* 1995;118 (Pt 6):1601-12.

18. Filippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. *Neurology* 1995;45:255-60.

19. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. *Brain* 1998;121 (Pt 1):3-24.

20. Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. *Neurology* 2001;57:2191-7.

21. Weiner HL, Guttmann CR, Khoury SJ, Orav EJ, Hohol MJ, Kikinis R, Jolesz FA. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. *J.Neuroimmunol.* 2000;104:164-73.

22. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. *Ann.Neurol.* 1997;42:783-93.

23. van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Nijeholt GJ, van d, V, Polman CH, Thompson AJ, Barkhof F. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. *Ann.Neurol.* 1999;46:747-54.

24. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, Polman CH, Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. *Neurology* 1998;50:1282-8.

25. Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, Mainero C, Horsfield M, Galgani S, Bastianello S, Buttinelli C. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. *Eur.J.Neurol.* 2002;9:645-55.

26. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DH. T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow-up study. *Eur.J.Neurol.* 2001;8:37-42.

27. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. *Neurology* 1996;47:1469-76.

28. van Walderveen MA, Barkhof F, Hommes OR, Polman CH, Tobi H, Frequin ST, Valk J. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. *Neurology* 1995;45:1684-90.

29. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Eight-year follow-up study of brain atrophy in patients with MS. *Neurology* 2002;59:1412-20.

30. Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R. A semiautomated measure of whole-brain atrophy in multiple sclerosis. *J.Neurol.Sci.* 2003;208:57-65.

31. Dastidar P, Heinonen T, Lehtimaki T, Ukkonen M, Peltola J, Erila T, Laasonen E, Elovaara I. Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. *J.Neurol.Sci.* 1999;165:36-42.

32. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. *Brain* 1996;119 (Pt 6):2009-19.

33. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. *Ann.Neurol.* 2006.

34. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann.Neurol.* 1983;13:227-31.

35. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology* 1996;46:907-11.

36. Lechner-Scott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, Tintore M, Frontoni M, Buttinelli C, Amato MP, Bartolozzi ML, Versavel M, Dahlke F, Kapp JF, Gibberd R. Can the Expanded Disability Status Scale be assessed by telephone? *Mult.Scler.* 2003;9:154-9.

37. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sorensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sa M, Salemi G, Savettieri G, Hillert J, Compston DA. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. *Neurology* 2005;64:1144-51.

38. Kalkers NF, Ameziane N, Bot JC, Minneboo A, Polman CH, Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. *Arch.Neurol.* 2002;59:1572-6.

39. Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF. MRI as a marker for disease heterogeneity in multiple sclerosis. *Neurology* 2005;65:1071-6.

40. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. *Brain* 2000;123 (Pt 11):2256-63.

41. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. *Mult.Scler.* 2003;9:21-7.

42. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. *J.Neurol.Neurosurg.Psychiatry* 2001;70:773-80.

43. Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. *Mult.Scler.* 2002;8:119-23.

44. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE, III, Brownscheidle CM. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Neurology* 1999;53:139-48.

45. Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. *Brain* 2001;124:1396-402.

46. Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. *Mult.Scler.* 2002;8:410-4.

47. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, Tomassini V, Millefiorini E, Bastianello S. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. *J.Neurol.Sci.* 2000;174:85-91.

48. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. *J.Neurol. Neurosurg.Psychiatry* 2002;73:141-7.

49. Dalton CM, Miszkiel KA, O'Connor PW, Plant GT, Rice GP, Miller DH. Ventricular enlargement in MS: one-year change at various stages of disease. *Neurology* 2006;66:693-8.

50. Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. *Brain* 2000;123 (Pt 5):1027-40.

51. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. *Mult.Scler.* 1995;1:37-47.

52. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. *Neurology* 2006;67:944-53.

53. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. *Lancet* 2007;**370**:389-97.